Increased Demand for Lipid Based Drug Delivery Systems along with Growth in Biologics & Specialty Pharmaceuticals is driving the Market, States Fact.MR

According to Fact.MR, a market research and competitive intelligence provider, the global lipids active pharmaceutical ingredient market is estimated to reach a valuation of US$ 3,422.1 million in 2024 and is expected to grow at a CAGR of 6.7% during the forecast period of (2024 to 2034).

The growing demand for lipid-based drug delivery systems, often considered among the novel drug delivery systems, is one of the leading factors propelling growth in the lipids API market. Encouraged by improved drug solubility, bioavailability, and controlled release profiles, lipids are critical in areas where the desired therapeutic effects are difficult to achieve due to the nature of the formulations. For instance, lipids enable drugs to bypass biological barriers, such as membranes around cells, and since the drug is delivered internally to a targeted tissue within the body, there is no particular need for the entire drug to circulate throughout the body.

This has enabled lipid active pharmaceutical ingredients (APIs) in the development of formulations for chronic diseases like the cardiovascular system and metabolic disorders due to the nature in which prolonged and accurate delivery of drugs is mandate. Within the last decade, however, new methods e.g. in lipid nanotechnology using lipid nanoparticles and liposomes have changed the outlook of lipid based delivery systems.

Another fundamental factor fueling the growth of the Lipids API market is the increasing use of biologics and specialty pharmaceuticals in recent medical practices. In this regard, most biologics, for example, monoclonal antibodies or vaccines as well as cell, and gene therapies, often lipid-based products, or emulsions, are designed to address optimization challenges associated with such drugs.

Lipid APIs are relatively more advantageous in such processes, especially when it comes to fabrication and delivery of biological drugs, which include vaccines and therapies such as mRNA because delivery systems of these agents are complex. In addition, the ability of lipids to achieve stability and enhance bioavailability makes them useful in developing sustained release profiles which are essential for specialty drugs that treat chronic illnesses.

The market for lipid APIs is expected to register solid growth from the long-term perspective, in light of the increasing demand of lipid based drug delivery systems along with high production of biologics and specialty pharmaceuticals, further reinforcing their significance in modern pharmaceuticals.

For More Insights into the Market, Request a Sample of this Report: https://www.factmr.com/connectus/sample?flag=S&rep_id=962

Key Takeaways from Market Study:

• The global lipids active pharmaceutical ingredient market is projected to grow at 6.7% CAGR and reach US$ 6,545.5 million by 2034.
• The market created an absolute $ opportunity of US$ 3,123.4 million growing at a CAGR of 6.7% between 2024 and 2034.
• North America is a prominent region that is estimated to hold a market share of 31.7% in 2034.
• Companies such as CordenPharma International, Avanti Polar Lipids, VAV Life Sciences, Cayman Chemical, and Merck KGaA are contributing in the lipids API market.
• By API type, phospholipids is estimated to grow from market value of US$ 1,232.0 Mn in 2024 to US$ 2,349.8 Mn upto 2034 creating an absolute $ opportunity of US$ 1,117.9 million between 2024 and 2034.
• North America and Western Europe are expected to create an absolute $ opportunity of US$ 1,657.6 million collectively.
• By application, pharmaceutical formulations is more prominent in the lipids active pharmaceutical ingredient market with an estimated value of US$ 2,637.8 Mn in 2034 with a growth rate of 6.9% between 2024 and 2034.

Key Players:

• CordenPharma International
• Avanti Polar Lipids
• VAV Life Sciences
• Cayman Chemical
• Merck KGaA
• Axplora
• EUROAPI
• KD Pharma Group
• Evonik Health Care
• Other Market Players

Country-wise Insights:

The United States market is valued at US$ 767.8 million in 2024 and is expected to grow at a CAGR of 6.8% between 2034. The United States market is expected to create an absolute opportunity of US$ 711.6 million during the period from 2024 to 2034.

The intensive level of lipid API's consumption in the market is due to the robust biopharmaceutical and pharmaceutical sectors in the U.S., which invests heavily in more research and the use of drug delivery systems based on lipids in the commercial arena

Economies with numerous biopharmaceutical and pharmaceutical companies, for example, the U.S., invest significantly in the development of innovative therapeutics from lipid formulation, for instance, biologics, gene therapies, and mRNA vaccines. These applications draw heavily on lipid APIs because of their capacity to enhance the bioavailability, stability, and targeted delivery of medicines which are vital components of cutting-edge therapies.

Category-wise Insights:

Demand for phospholipids is expected to reach at a value of US$ 2,349.8 Mn by 2034 at a compound annual growth rate of 6.7% from 2024-2034.

Phospholipids are in highest demand for products in the lipid active pharmaceutical ingredient market due to their efficient use in sophisticated drug delivery systems. The hydrophobic and hydrophilic nature of phospholipids allows them to form lipid bilayers which are the major components of cell membranes. This characteristic also promotes the application of phospholipids in liposomal and lipid nanocarrier systems, which are major exhaust systems for therapeutically active agents.

Lipids Active Pharmaceutical Ingredient Market News:

• In June 2024, CordenPharma, a worldwide CDMO in Drug Substance manufacturing (APIs) entered into partnership with Certest, a Spanish enterprise dedicated to the creation of new products in the field of drug delivery using Lipid Nano Particles (LNPs) and API synthesis. The agreement will introduce the addition of ionizable lipids to CordenPharma's advanced LNP formulation services.
• In May 2022, EUROAPI which is a global leader in lipid nanoparticles expanded its collaboration with Sanofi for their agreement regarding development and GMP manufacturing services, to support Sanofi’s mRNA vaccine platform with the development of lipid nanoparticles.

Get Customization on this Report for Specific Research Solutions: https://www.factmr.com/connectus/sample?flag=S&rep_id=962

More Valuable Insights on Offer

Fact.MR, in its new offering, presents an unbiased analysis of the global lipids active pharmaceutical ingredient market, presenting historical data for 2019 to 2023 and forecast statistics for 2024 to 2034.

The study reveals essential insights on the basis of API Type (Phospholipids, Sphingolipids, Fatty Acids, Triglycerides, and Other Lipids (Cholesterol, Glycolipids)); By Indication (Cardiovascular Disorders, Cancer, Neurological Disorders, Diabetes, Infectious Diseases, Autoimmune Diseases, and Other Indications); By Application (Pharmaceutical Formulations, Nutraceuticals, Cosmetics & Personal Care, Dietary Supplements, and Other Applications); By End User (Pharmaceutical Companies, Contract Manufacturing Organizations (CMOs), Research & Academic Institutes, Nutraceutical Companies, Cosmetic Manufacturers, and Other End Users across major regions of the world (North America, Latin America, Western Europe, Eastern Europe, East Asia, South Asia & Pacific, and Middle East & Africa).

Check out More Related Studies Published by Fact.MR Research:

Medical Equipment Maintenance Market size is approximated at a value of US$ 47.8 billion in 2024 and is forecasted to expand at a CAGR of 7.5% to reach US$ 98.6 billion by 2034-end.

Whole Slide Imaging System Market are estimated at US$ 446.5 million in 2024 and have been analyzed to climb to US$ 1.08 billion by the end of 2034. The whole slide imaging system market has been forecasted to increase at 9.2% CAGR from 2024 to 2034.

Pulmonary Fibrosis Treatment Market The global pulmonary fibrosis treatment market size is analyzed to increase from US$ 3.29 billion in 2024 to US$ 6.07 billion by the end of 2034.

Alcohol Breathalyzer and Drug Testing Equipment Market size is calculated at a value of US$ 18.37 billion in 2024 and is forecasted to expand at a CAGR of 7.3% to reach US$ 37.26 billion by 2034.

Bone Mineral Densitometry (BMD) Market is estimated at a value of US$ 351.2 million in 2024 and is projected to expand at a CAGR of 3.5% to reach US$ 495.1 million by the end of 2034.

Computerized Physician Order Entry (CPOE) System Market is estimated at US$ 1.92 billion in 2024. It has been forecasted to increase at a CAGR of 6.6% to reach US$ 3.64 billion by the end of 2034.

Opioid Overdose Treatment Market is valued at US$ 1.54 billion in 2024, as revealed in a newly published report by Fact.MR. Over the assessment period (2024 to 2034), the market is forecasted to advance at a CAGR of 7.2% and reach a US$ 3.1 billion by the end of 2034.